Frontera Therapeutics Receives Additional IND Clearance for its Lead Program FT-001
September 21, 2022 08:00 ET | Frontera Therapeutics
BEDFORD, Mass. and SHANGHAI, China, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Frontera Therapeutics, a global clinical-stage biotechnology company that seeks to develop novel and best-in-class gene therapy...
Frontera Therapeutics Completes $160 Million Series B Financing to Fund Clinical Development and Manufacturing Capabilities
July 19, 2022 08:00 ET | Frontera Therapeutics
FDA clears Investigational New Drug (IND) application for lead gene therapy product candidate, FT-001, for the treatment of a rare inherited eye disease leading to severe visual impairment that may...